

List of all

Data from

Added	Go to www.clinicaltrials.gov and search this NCT Number for more detail	Indication	Title	abbreviated in and exclusion criteria - Go to www.clinicaltrials.gov and search NCT Number for more detail	Locations	Contact (please note some contacts are international) Use NCT number as reference	Sponsor	Phase	Start Date	Planned Completion Date
2016/11/01	NCT00725387	Any Cancer	Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy (only scan for malignancy, no treatment)	Patients older than 18-year-old, diagnosed with cancer	Pretoria Academic Hospital	Andrei Iagaru 00 650-736-2859 aiagaru@stanford.edu	Stanford University	observational	01 August 2007	01 December 2018
2016/02/01	NCT00858364	Lung Cancer	Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy	stage IV Non -small cell lung cancer with anemia	Bloemfontein, Johannesburg, Durban,	Tel 011 612 8600	Amgen	Phase 3	01 June 2009	01 June 2019
2016/02/01	NCT00957086	Head and Neck cancer	Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer	after operation, locally advanced head and neck cancer no evidence of distant metastasis.	Durban, Cape Town	Dr Jo Ann James Durban joann@medi.co.za Sheila Visser Durban glanders2@medi.co.za Dr Conrad Jacobs Panorama Conrad.Jacobs@cancercares.co.za	National Medical Research Council (NMRC), Singapore Innogene Kalbiotech Pte. Ltd	Phase 3	01 August 2009	01 June 2021
2016/02/01	NCT01200589	Non-Hodgkin's Lymphoma	Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy	B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy	Johannesburg, PE,Amazintoti	GSKClinicalSupportHD@gsk.com	GlaxoSmithKline	Phase 3	01 October 2010	01 September 2020
2016/02/01	NCT01352117	Kaposi's Sarcoma	Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma	HIV	Durban, Johannesburg	Pauline Vunandlala 011-2768800 pvunandlala@witshealth.co.za ; Dr Rosie Mngqibisa 031-2604469 mngqibisa@ecarefoundation.com	AIDS Clinical Trials Group National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	01 October 2011	01 October 2020

Added	Go to www.clinicaltrials.gov and search this NCT Number for more detail	Indication	Title	abbreviated in and exclusion criteria - Go to www.clinicaltrials.gov and search NCT Number for more detail	Locations	Contact (please note some contacts are international) Use NCT number as reference	Sponsor	Phase	Start Date	Planned Completion Date
2016/06/30	NCT01435018	Kaposi's Sarcoma	A Randomized Comparison of Three Regimens of Chemotherapy With Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings	HIV-1 infection, Karposi Sarcoma	Durban Adult HIV CRS (11201)4013 SF Principal Investigator: Umesh Gangaram Lalloo, MD, FRCP University of Witwatersrand Johannesburg	Contact: Fawzia Williamson 27 31 260 4365 amodf1@nu.ac.za Contact: Pauline S Vunandlala, BSc. 27 11 717 2810 idsyndicate@witshealth.co.za	AIDS Clinical Trials Group	phase III	01 August 2013	01 June 2027
2016/11/01	NCT01479283	Bone cancer	Prophylactic Antibiotic Regimens in Tumor Surgery	primary malignant or aggressive benign bone tumors of the lower extremity, or soft-tissue sarcomas which have invaded the bone; and treatment by surgical excision and endoprosthesis replacement. Older than 12 years.	Grey's Hospital Pietermaritzburg, South Africa Principal Investigator: Reitze Rodseth, MBChB	Paula McKay, B.Sc (905) 527-4322 ext 44131 mckayp@mcmaster.ca	McMaster University	observational	01 January 2013	01 December 2019
2016/02/01	NCT01772472	Breast cancer	A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)	HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Following Preoperative Therapy Not metastatic cancer	Johannesburg, Cape Town, Port Elizabeth, Pietermaritzburg, Pretoria	Contact: Reference Study ID Number: B027938 Tel 011 5025027	Hoffmann-La Roche German Breast Group NSABP Foundation Inc	Phase 3	01 April 2013	01 March 2023
2016/02/01	NCT01846611	Ovarian cancer	A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer	Pretoria, Cape Town, Johannesburg, PE, Amanzimtoti, Durban	Tel 011 518 7000	Janssen Research & Development, LLC PharmaMar	Phase 3	01 October 2013	01 September 2018

Added	Go to www.clinicaltrials.gov and search this NCT Number for more detail	Indication	Title	abbreviated in and exclusion criteria - Go to www.clinicaltrials.gov and search NCT Number for more detail	Locations	Contact (please note some contacts are international) Use NCT number as reference	Sponsor	Phase	Start Date	Planned Completion Date
17/09/27	NCT01846611	Gynecology cancers	A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	adult female patients with platinum-sensitive advanced - relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer who received 2 previous lines of platinum - based chemotherapy	Rainbow Oncology Amanzimtoti, GVI Oncology Cape Town, The Oncology Centre Durban, University of Witwatersrand, Department of Medical Oncology Johannesburg, Sandton Oncology Centre Johannesburg, Langenhoven Drive Oncology Port Elizabeth, Mary Potter Oncology Centre - Little Company Of Mary Pretoria,	Contact sites directly or http://pam.sylogent.com/cr/CR100983	Janssen	III	16 October 2013	12 September 2018
2016/06/30	NCT01907100	Mesothelioma	LUME-Meso: Phase II/III Study of Nintedanib With Pemetrexed / Cisplatin Followed by Continuing Nintedanib Monotherapy vs Placebo With Pemetrexed / Cisplatin Followed by Continuing Placebo Monotherapy for Unresectable Malignant Pleural Mesothelioma	Confirmed malignant pleural mesothelioma (MPM) Previous systemic chemotherapy for MPM	1199.93.27001 Boehringer Ingelheim Investigational Site Pretoria, South Africa	Contact: Boehringer Ingelheim Call Center 001-800-243-0127 (USA number) or email clintriage.rdg@boehringer-ingelheim.com	Boehringer Ingelheim	phase III	01 September 2013	01 October 2019
2016/02/01	NCT01989676	Breast cancer	A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)	First-Line Treatment Of Patients With HER2-positive Metastatic Breast Cancer, not in heartfailure	Cape Town, Amanzimtoti, Johannesburg, PE, Pretoria	Prof L Dreosti Telephone: 012 354 1054	Pfizer	Phase 3	01 February 2014	01 February 2018

Added	Go to www.clinicaltrials.gov and search this NCT Number for more detail	Indication	Title	abbreviated in and exclusion criteria - Go to www.clinicaltrials.gov and search NCT Number for more detail	Locations	Contact (please note some contacts are international) Use NCT number as reference	Sponsor	Phase	Start Date	Planned Completion Date
2016/02/01	NCT02125461	Lung Cancer	A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer	locally advanced, unresectable, Stage III lung cancer, already had 2 cycles of platinum-based chemotherapy concurrent with radiation therapy.	Bloemfontein, Cape Town, Johannesburg, Pretoria, Vereeniging	Prof P Ruff Telephone: +27114884452	AstraZeneca	Phase 3	01 May 2014	01 January 2020
2016/02/01	NCT02181413	Multiple Myeloma	A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant	symptomatic multiple myeloma who already had a bone marrow transplant	Johannesburg, Pretoria	Heindrich Pienaar Telephone: 011 612 8600	Millennium Pharmaceuticals, Inc.	Phase 3	01 July 2014	01 February 2018
2016/02/01	NCT02200614	Prostate cancer	Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer (ARAMIS)	prostate cancer not responding on castration No metastasis	George, PE, Johannesburg, Pretoria, Durban, Paarl, Cape Town, Somerset-west	Dr Lance Coetzee - National Principal Investigator Telephone: +27 12 342 9432	Bayer	Phase 3	01 September 2014	01 June 2020
2016/02/01	NCT02220894	Lung Cancer	Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)	advanced or metastatic Non-small cell lung cancer, had no prior systemic chemotherapy for the advanced or metastatic disease	Johannesburg	Contact: Khanyi Mzolo 011 655 3140	Merck Sharp & Dohme Corp.	Phase 3	01 October 2014	01 July 2019
2016/02/01	NCT02257736	Prostate cancer	An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)	did not receive any chemotherapy for metastatic castration-resistant (low testosterone) prostate cancer	Bloemfontein, Cape Town, Johannesburg, Pretoria	Tel 011 518 7000	Janssen Research & Development, LLC	Phase 3	01 November 2014	01 August 2021

Added	Go to www.clinicaltrials.gov and search this NCT Number for more detail	Indication	Title	abbreviated in and exclusion criteria - Go to www.clinicaltrials.gov and search NCT Number for more detail	Locations	Contact (please note some contacts are international) Use NCT number as reference	Sponsor	Phase	Start Date	Planned Completion Date
12/07/2017	NCT02263508	Melanoma	Pembrolizumab With or Without Talmogene Laherparepvec or Talmogene Laherparepvec Placebo in Unresected Melanoma (KEYNOTE-034)	Melanoma and stage IIIB to IVM1c for whom surgery is not recommended. Subjects must be a candidate for intralesional therapy administration into cutaneous, subcutaneous, or nodal lesions. Subjects with BRAFV600 wild-type tumors without any prior chemotherapy, immunotherapy, or targeted therapy given Prior BRAF inhibitor therapy either alone or in combination with MEK inhibitor as the only prior systemic therapy is allowed Key Exclusion Criteria: Brain metastases. Subjects must not have primary eye or mucosal melanoma, history or evidence of melanoma associated with immunodeficiency states or history of other malignancy within the past 3 years.	Research Site Groenkloof 0181 Johannesburg, 2196 Kraaifontein, 7570 Pretoria, 0002 Pretoria, 0081	Contact: Amgen Call Center 00 866-572-6436 medinfo@amgen.com	Amgen	Phase 3	08 December 2014	31 December 2018
2016/02/01	NCT02272413	Lung Cancer	Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With advanced Lung Cancer	Advanced Nonsquamous Non-Small Cell Lung Cancer Recurrent or metastatic disease (Stage IV)	Cape Town, George, Johannesburg	Dr Breedt 0836297693 (ref WWA16924) Boehringer Ingelheim Call Center 1-800-243-0127 clintrriage.rdg@boehringer-ingelheim.com	Boehringer Ingelheim	Phase 3	01 July 2015	01 March 2019

Added	Go to www.clinicaltrials.gov and search this NCT Number for more detail	Indication	Title	abbreviated in and exclusion criteria - Go to www.clinicaltrials.gov and search NCT Number for more detail	Locations	Contact (please note some contacts are international) Use NCT number as reference	Sponsor	Phase	Start Date	Planned Completion Date
	NCT02312258	Multiple Myeloma	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation	Adult male or female confirmed diagnosis of newly diagnosed multiple myeloma, completed 6 to 12 months of initial therapy	Albert Alberts Stem Cell Transplant Centre Pretoria, Gauteng, South Africa, 0044	Call Center +1-844-662-8532 or globaloncologymedinfo@takeda.com	Takeda	phase 3	01 April 2015	01 December 2018
12/07/2017	NCT02322814	Breast cancer	A Study of Cobimetinib in Combination With Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, and Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as First-line Treatment for Participants With Metastatic Triple-Negative Breast Cancer	Histologically confirmed estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor 2 (HER2)-negative adenocarcinoma of the breast with measurable metastatic or locally advanced disease	Cape Town Oncology Trials, Mary Potter Oncology Centre Groenkloof, Wits Donald Gordon Clinical Trial Site Johannesburg, Langenhoven Drive Oncology Centre Port Elizabeth, Steve Biko Academic Hospital Oncology Pretoria, Eastleigh Breast Care Centre Pretoria	Contact: Reference Study ID Number: WO29479 www.roche.com/about_roche/roche_worldwide.htm Tel 00 888-662-6728 Email global-roche-genentech-trials@gene.com	Roche	Phase 2	25 November 2014	31 July 2018
2016/02/01	NCT02358031	Head and Neck cancer	A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)	recurrent or metastatic cancer of the head and neck No treatment received for the recurrent or metastatic setting	Johannesburg	Contact: Khanyi Mzolo 011 655 3140	Merck Sharp & Dohme Corp.	Phase 3	01 March 2015	01 September 2018
2016/02/01	NCT02364999	Lung Cancer	A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC	Newly diagnosed Stage IIIB or IV non-small cell lung cancer had not received chemotherapy for metastatic disease	PE, Johannesburg, Amanzimtoti, Cape Town	Dr CR Jacobs 021 944 3830	Pfizer	Phase 3	01 April 2015	01 January 2018

Added	Go to www.clinicaltrials.gov and search this NCT Number for more detail	Indication	Title	abbreviated in and exclusion criteria - Go to www.clinicaltrials.gov and search NCT Number for more detail	Locations	Contact (please note some contacts are international) Use NCT number as reference	Sponsor	Phase	Start Date	Planned Completion Date
2016/02/01	NCT02367040	Non-Hodgkin's Lymphoma	Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)	CD20 positive Indolent non-Hodgkin's lymphoma that have relapsed after at least 1 prior line of therapy, including rituximab and alkylating agents.	Johannesburg, Pretoria, George	clinical-trials-contact@bayerhealthcare.com Marlize Schmitt Theron Telephone: 011 921 5065	Bayer	Phase 3	01 June 2015	01 December 2020
2016/02/01	NCT02370498	Stomach cancer	A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)	metastatic or locally advanced stomach cancer that can't be operated on.	Johannesburg	Contact: Khanyi Mzolo: Tel 011 655 3140 Zoe Nell Tel 011 655 3000	Merck Sharp & Dohme Corp.	Phase 3	01 May 2015	01 February 2018
17/09/27	NCT02379845	Sarcoma	NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating and Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall	Locally Advanced Soft Tissue Sarcoma of the Extremity and Trunk Wall; all grades, including Locally advanced unresectable low grade tumor; Candidate for radiotherapy i.e. unresectable tumor or unfeasible carcinological surgery	Iatros International Bloemfontein, The Oncology Centre Durban, Gvi Outeniqua Oncology Unit George, Wilgers Oncology Centre Pretoria	Contact: Mikaela DIMITRIU, PhD mikaela.dimitriu@nanobiotix.com Contact: Elsa BORGHI, MD elsa.borghi@nanobiotix.com	Nanobiotix	II/III	01 February 2015	01 December 2019
2016/05/24	NCT02388906	Melanoma	Efficiency study of Nivolumab compared to Ipilimumab in prevention of recurrence of melanoma after complete resection of stage IIIb/c or Stage IV Melanoma	Completely removed melanoma by surgery performed within 12 weeks of randomization Stage IIIb/C or Stage IV before complete resection No previous anti-cancer treatment	Johannesburg, 2199 Pretoria, 0181 Saxonwold, Johannesburg, 2196 Cape Town 7570 Rondebosch 7700	Adrie Jacobs Telephone: +27 11 808 5488	BMS/Ono Pharmaceutical Co/Ltd	phase 3	01 March 2015	01 November 2019

Added	Go to www.clinicaltrials.gov and search this NCT Number for more detail	Indication	Title	abbreviated in and exclusion criteria - Go to www.clinicaltrials.gov and search NCT Number for more detail	Locations	Contact (please note some contacts are international) Use NCT number as reference	Sponsor	Phase	Start Date	Planned Completion Date
2016/02/01	NCT02395172	Lung cancer	A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus docetaxel in subjects with non-small cell lung cancer that has progressed after a platinum-containing doublet	Subjects with histologically confirmed Stage IIIb/IV or recurrent NSCLC who have experienced disease progression	Cape Town, PE, Pretoria	Dr Breedt: 0836297693	Merck Serono	Phase 3	15 March 2016	01 November 2022
2016/02/01	NCT02395172	Lung Cancer	Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)	Stage IIIb/IV or recurrent NSCLC who have experienced disease progression	Cape Town, PE, Pretoria	083 629 7693	EMD Serono/Merck KGaA	Phase 3	01 March 2015	01 October 2021
2016/02/01	NCT02447003	Breast cancer	Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)	metastatic triple-negative breast cancer	Johannesburg	Contact: Khanyi Mzolo 011 655 3140	Merck Sharp & Dohme Corp.	Phase 2	01 June 2015	01 November 2019
2016/02/01	NCT02467907	Cervix cancer	Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Recurrent Metastatic, Cervical Cancer	Distant metastatic, recurrent or persistent cancer of the cervix that can not be treated with surgery and/or radiation therapy	Johannesburg, Pietermaritzburg, Pretoria	Contact: Reference Study ID Number: MQ29594 Tel '011 5025027	Hoffmann-La Roche	Phase 2	01 July 2015	01 January 2019
2016/03/30	NCT02477826	Lung cancer	An Open-Label, Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC)	Chemotherapy-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer	Johannesburg 2199	Adrie Jacobs Telephone: +27 11 808 5488	BMS	phase 3	01 August 2015	01 December 2020
17/09/27	NCT02477826	Non-small cell lung cancer	An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)	histologically confirmed Stage IV or recurrent NSCLC squamous or non-squamous histology, with no prior systemic anticancer therapy	Johannesburg, Pretoria, Vereeniging	Clinical.Trials@bms.com First line of the email MUST contain NCT# and Site #.	Bristol-Myers Squibb	III	01 August 2015	01 December 2020

Added	Go to www.clinicaltrials.gov and search this NCT Number for more detail	Indication	Title	abbreviated in and exclusion criteria - Go to www.clinicaltrials.gov and search NCT Number for more detail	Locations	Contact (please note some contacts are international) Use NCT number as reference	Sponsor	Phase	Start Date	Planned Completion Date
2016/02/01	NCT02494583	Stomach cancer	Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)	advanced stomach cancer Has not yet had chemotherapy	Johannesburg	Contact: Khanyi Mzolo 011 655 3140	Merck Sharp & Dohme Corp.	Phase 3	01 July 2015	01 April 2019
2016/03/30	NCT02538666	Lung Cancer	A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy	Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy	Johannesburg 2199 Cape Town 7570 George 6530 Rondebosch 7700	Adrie Jacobs Telephone: +27 11 808 5488	BMS	phase 3	01 September 2015	01 June 2019
2016/06/30	NCT02563002	Colon cancer	A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)	Locally confirmed stage IV colorectal carcinoma, no brain metastases, no immunosuppressive drugs or cortisone used	MSD (Pty) LTD South Africa Midrand, South Africa	Contact: Khanyi Mzolo 27 11 655 3140	Merck Sharp & Dohme Corp.	Phase III	15 November 2016	01 August 2019
2016/02/01	NCT02573324	Glioblastoma	A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification	Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) positive	Cape Town	Contact: Kathy Kim, MS 00847-938-0255 kathy.kim@abbvie.com Contact: Kysa Meek 00847-938-1090 kysa.a.meek@abbvie.com Telephone: 011 858 2163/ 011 858 2037	AbbVie Radiation Therapy Oncology Group	Phase 2	01 December 2015	01 March 2020

Added	Go to www.clinicaltrials.gov and search this NCT Number for more detail	Indication	Title	abbreviated in and exclusion criteria - Go to www.clinicaltrials.gov and search NCT Number for more detail	Locations	Contact (please note some contacts are international) Use NCT number as reference	Sponsor	Phase	Start Date	Planned Completion Date
2016/05/24	NCT02576275	multiple myeloma	A Phase III Study of Lenalidomide and Low-dose Dexamethasone With or Without Pembrolizumab (MK3475) in Newly Diagnosed and Treatment naive Multiple Myeloma (KEYNOTE 185).	active multiple myeloma that can't be treated with stem-cell transplantation due to age (≥65 years old) or any significant coexisting medical condition	Johannesburg	Contact: Khanyi Mzolo 27 11 655 3140	MSD (Pty) LTD South Africa	phase III	01 October 2015	01 March 2019
2016/05/24	NCT02576574	Non Small Cell Lung Cancer	Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 100)	Subjects with histologically confirmed metastatic or recurrent non-small cell lung cancer (NSCLC) Subjects must not have received any treatment for systemic lung cancer,	GVI Cape Gate Oncology Centre Recruiting Cape Town, Western Cape, South Africa, 7570 Principal Investigator: Conrad Jacobs	Contact: Sylvia Holdt +27219443830 sylvia.holdt@cancercare.co.za	EMD Serono Research & Development Institute, Inc. Merck KGaA EMD Serono	Phase 3	01 October 2015	01 June 2023
2016/11/01	NCT02579863	Multiple Myeloma	Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)	Confirmed diagnosis of active multiple myeloma and measurable disease. Ineligible to receive treatment with auto-Stem cell transplant due to age (≥65 years old) or any significant coexisting medical condition	Unknown	MSD (Pty) LTD South Africa Recruiting Midrand, South Africa Contact: Khanyi Mzolo 27 11 655 3140	MSD (Pty) LTD South Africa	open label	01 October 2015	01 March 2019
12/07/2017	NCT02626455	Lymphoma	Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)	Histologically confirmed diagnosis of CD20 positive iNHL. Patients must have relapsed after at least 1 but at most 3 prior lines of therapy, no HIV or hepatitis, no heart failure	Kimberley, Northern Cape, South Africa, 8301	Contact: clinical-trials-contact@bayer.com Contact: Bayer US toll-free number 00 1-888-84 22937	Bayer	Phase 3	06 January 2016	30 September 2021

Added	Go to www.clinicaltrials.gov and search this NCT Number for more detail	Indication	Title	abbreviated in and exclusion criteria - Go to www.clinicaltrials.gov and search NCT Number for more detail	Locations	Contact (please note some contacts are international) Use NCT number as reference	Sponsor	Phase	Start Date	Planned Completion Date
2016/06/30	NCT02628067	Advanced cancer	A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)	Histologically or cytologically-documented, advanced solid tumor. Progression of tumor or intolerance to therapies known to provide clinical benefit. There is no limit to the number of prior treatment regimens	Johannesburg	Contact: Khanyi Mzolo 27 11 655 3140	MSD (Pty) LTD South Africa	phase II	01 December 2015	01 April 2021
2016/06/30	NCT02657434	Non Small Cell Lung Cancer	Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer	Histologically or cytologically confirmed, Stage IV non-squamous NSCLC. No prior treatment for Stage IV non-squamous NSCLC. No brain metastases	George, South Africa, 6530 Groenkloof, South Africa, 0181 Port Elizabeth, South Africa, 6045 Pretoria, South Africa, 0157 Pretoria, South Africa, 0002	Reference Study ID Number: GO29438 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. and Canada) global.roche.genentechtrials@roche.com '011 502 5027	Hoffmann-La Roche	Phase III	01 April 2016	01 January 2019
2016/06/30	NCT02674061	advanced ovarian cancer	A Phase II, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy and Safety of Pembrolizumab Monotherapy in Subjects With Advanced Recurrent Ovarian Cancer (KEYNOTE-100)	epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, adequate organ function, do not have an active autoimmune disease	Johannesburg	Contact: Khanyi Mzolo 011 655 3140	Merck Sharp & Dohme Corp.	phase II	01 February 2016	01 March 2020
	NCT02684292	Hodgkin Lymphoma	A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma	Has relapsed or resistant classical Hodgkin Lymphoma.	Unknown	Contact: Khanyi Mzolo 011 655 3140	Merck Sharp & Dohme Corp.	phase III	23 May 2016	30 December 2018

Added	Go to www.clinicaltrials.gov and search this NCT Number for more detail	Indication	Title	abbreviated in and exclusion criteria - Go to www.clinicaltrials.gov and search NCT Number for more detail	Locations	Contact (please note some contacts are international) Use NCT number as reference	Sponsor	Phase	Start Date	Planned Completion Date
2017/03/28	NCT02750202	Genital warts	Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts (TheraVACCS)	Female patient > 16 years with vulvo vaginal genital warts, HIV negative or HIV infected and CD4 ≥ 300 cells/mm ³ OR viral load controlled OR anti retroviral (ARV) compliant > 6 months	Pretoria	Steve Biko Academic Hospital Contact: Cathy Visser, MSc +27 12 354 3900 visser.cathy@gmail.com Principal Investigator: Leon C Snyman, MMedO&G;FCOG	University of Pretoria	phase 3	01 July 2016	01 June 2019
2016/09/13	NCT02752074	Melanoma	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma	Have histologically or cytologically confirmed melanoma Have unresectable Stage III or Stage IV melanoma, as per AJCC staging system not amenable to local therapy	Johannesburg, Sandton, Groenkloof, Pretoria, Cape Town, Kraaifontein	Contact: Incyte Corporation Call Center 001 855 463 3463	Incyte	phase III	01 June 2016	01 May 2018
2016/09/13	NCT02763566	Breast Cancer	A Phase 3 Study to Compare NSAI (Anastrozole or Letrozole) Plus Abemaciclib, a CDK4 and CDK6 Inhibitor, or Plus Placebo, and to Compare Fulvestrant Plus Abemaciclib or Plus Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer	A diagnosis of HR+, HER2- breast cancer with local recurrent disease not amenable to resection or radiation therapy, or metastatic disease. Postmenopausal.	Pretoria and Johannesburg	contact 01-877-CTLILLY (01-877-285-4559, 01-317-615-4559 between 15h00 and 18h00	Eli Lilly	phase III	01 October 2016	01 December 2019
2016/05/24	NCT02765503	Head and Neck cancer	Resource-Sparing Curative radiotherapy for locally advanced squamous cell cancer of the head and neck (HYPNO)	Stage I-IV tumor of oropharynx, hypopharynx, larynx , or oral cavity Must be a candidate for external beam radical radiotherapy Must have no HIV or distant metastasis	University of Pretoria Pretoria, South Africa	Contact: Roy Lakier roy.lakier@up.ac.za	International Atomic Energy Agency	Phase 3	01 March 2014	01 November 2021

Added	Go to www.clinicaltrials.gov and search this NCT Number for more detail	Indication	Title	abbreviated in and exclusion criteria - Go to www.clinicaltrials.gov and search NCT Number for more detail	Locations	Contact (please note some contacts are international) Use NCT number as reference	Sponsor	Phase	Start Date	Planned Completion Date
2016/06/30	NCT02807636	Bladder and urinary tract cancer	A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti PD-L1 Antibody) in Combination With Gemcitabine/Carboplatin Versus Gemcitabine/Carboplatin Alone in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible For Cisplatin-Based Therapy	Locally advanced or metastatic transitional cell carcinoma [TCC] or urothelial cell carcinoma [UCC] of the urinary tract; including renal pelvis, ureters, urinary bladder, and urethra. No prior chemotherapy for inoperable locally advanced or metastatic cancer. No active or untreated brain metastases	Port Elizabeth, South Africa, 6045 Pretoria, South Africa, 0002 Sandton, South Africa, 2196	Reference Study ID Number: WO30070 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. and Canada) global.roche.genentechtrials@roche.com 011 502 5027	Hoffmann-La Roche	phase III	01 June 2016	01 September 2019
17/09/27	NCT02809053	Follicular lymphoma	A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma	Asymptomatic patients with Low Tumor Burden Follicular Lymphoma, no previous treatment with any chemotherapy and/or rituximab or other monoclonal antibody.	Pretoria	info@archigenbio.com	Archigen	III	18 January 2017	01 July 2018
2016/11/01	NCT02823574	Head and Neck cancer	A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)	Confirmed squamous cell head and neck cancer Widespread (metastatic) disease, or returned after previous treatment (recurrent)	Port Elizabeth, Eastern Cape, Site 0036 Johannesburg, Gauteng, Site 0017 Pretoria, Gauteng, Site 0019 Rondebosch, Site 0018	Clinical.Trials@bms.com Contact: First line of the email MUST contain NCT# and Site #.	BMS	phase II	01 September 2016	01 October 2018
12/07/2017	NCT02853305	Bladder and urinary tract cancer	Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)	Advanced/unresectable (inoperable) or metastatic urothelial carcinoma of the renal pelvis, ureter [upper urinary track], bladder, or urethra. No HIV, hepatitis, TB.	unknown	MSD (Pty) LTD South Africa Recruiting Midrand, South Africa Contact: Khanyi Mzolo 27 11 655 3140	MSD	Phase 3	15 September 2016	29 January 2019

Added	Go to www.clinicaltrials.gov and search this NCT Number for more detail	Indication	Title	abbreviated in and exclusion criteria - Go to www.clinicaltrials.gov and search NCT Number for more detail	Locations	Contact (please note some contacts are international) Use NCT number as reference	Sponsor	Phase	Start Date	Planned Completion Date
2017/03/28	NCT02899299	Mesothelioma	Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients	pleural malignant mesothelioma not eligible for curative surgery	Cape Town	please email: Clinical.Trials@bms.com First line of the email MUST contain NCT# and Site number 0059	Bristol-Myers Squibb	phase 3	01 October 2016	01 September 2021
12/07/2017	NCT02956031	Cervix cancer screening	Screening Study for Cervical Pre-cancer and Cancer Prevention in South African Women.	Exclusion Criteria: Current pregnancy, Hysterectomy, Current or previous treatment for gynaecological cancer	Pretoria Steve Biko Hospital	Contact: Greta Dreyer, PhD +(27) 12 354 3900 greta.dreyer@up.ac.za Contact: Cathy Visser, MSc +(27) 12 354 3900 cathy.visser@up.ac.za	Univ of Pretoria	observational	02 November 2016	01 November 2019
12/07/2017	NCT02960022	Prostate cancer	A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study	Subject must currently be receiving enzalutamide for prostate cancer in a study sponsored by Astellas or Medivation and, based on the investigator's assessment, benefit from continued treatment.	Site ZA27001 George, South Africa, 6529	Contact: Astellas Pharma Global Development Tel 00 800-888-7704 ext 5473 email: astellas.registration@astellas.com	Astellas	Phase 2	22 December 2016	01 July 2021
12/07/2017	NCT02993523	Leukemia	A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Na ⁺ ve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy	Acute Myeloid Leukemia (AML), not legible for treatment with a standard cytarabine and anthracycline induction regimen due to age or comorbidities.	Tshwane District Hospital /ID# 153682 Pretoria Netcare Pretoria East Hospital /ID# 153684 Pretoria	Contact: AbbVie_Call Center 00 847 283 8955 email: abbvieclinicaltrials@abbvie.com	AbbVie	phase 3	02 February 2017	01 February 2020

Added	Go to www.clinicaltrials.gov and search this NCT Number for more detail	Indication	Title	abbreviated in and exclusion criteria - Go to www.clinicaltrials.gov and search NCT Number for more detail	Locations	Contact (please note some contacts are international) Use NCT number as reference	Sponsor	Phase	Start Date	Planned Completion Date
12/07/2017	NCT03033511	Lung cancer	A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)	extensive-stage disease small cell lung cancer (ED SCLC) with ongoing clinical benefit following completion of 4 cycles of first-line platinum-based therapy	The Oncology Centre /ID# 158872 Durban 4001 Langenhoven Drive Oncology Centre /ID# 159126 Port Elizabeth 6045 Mary Potter Oncology Centre /ID# 158877 Pretoria 0181 Wilgers Oncology Centre /ID# 158873 Pretoria 0081	Contact: AbbVie_Call Center 00 847 283 8955 email: abbvieclinicaltrials@abbvie.com	AbbVie	Phase 3	07 February 2017	14 November 2019
2017/03/28	NCT03049189	Neuro-endocrine tumours	Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE)	Patients With Inoperable, Progressive, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumours of Gastroenteric or Pancreatic Origin	Pretoria Steve Biko Hospital	Contact: Dr Konstantin Zhernosekov, info@itm-solucin.de Contact: DR Ulrike Schorr-Neufing, info@abx-cro.com	ITM Solucin GmbH	phase 3	01 February 2017	01 May 2021
12/07/2017	NCT03069352	Leukemia	A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naïve Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy	Acute Myeloid Leukemia (AML) and is not legible for intensive induction chemotherapy	Tshwane District Hospital /ID# 157361 Pretoria, South Africa, 0001	Contact: AbbVie_Call Center 00 847 283 8955 email: abbvieclinicaltrials@abbvie.com	AbbVie	Phase 3	24-May-17	02-Dec-19
	NCT03090737	Advanced or Metastatic Non-small Cell Lung Cancer	An Open-label, Single-arm Phase II Safety Study of Nivolumab in Participants With Advanced or Metastatic Non-small Cell Lung Cancer Who Have Progressed During or After Receiving at Least One Prior Systemic Regimen	Non small cell lung cancer (Squamous or non-squamous) One prior anti-cancer therapy that did not work	Port Elizabeth, Eastern CAPE, Site 11 Parktown, Johannesburg, Gauteng, Site 13 George, Western CAPE, Site 12	please email: Clinical.Trials@bms.com First line of the email MUST contain NCT # and Site #.	BMS	Phase II	26 May 2017	29 April 2020

Added	Go to www.clinicaltrials.gov and search this NCT Number for more detail	Indication	Title	abbreviated in and exclusion criteria - Go to www.clinicaltrials.gov and search NCT Number for more detail	Locations	Contact (please note some contacts are international) Use NCT number as reference	Sponsor	Phase	Start Date	Planned Completion Date
17/09/27	NCT03155997	Breast cancer	A Study to Compare Treatment After Surgery of Abemaciclib (LY2835219) Combined With Standard Endocrine Therapy Versus Endocrine Therapy Alone in Participants With Breast Cancer	Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer	Cape Town, George, Johannesburg, Port Elizabeth, Pretoria	1-877-CTLILLY (1-877-285-4559, 1-317-615-4559)	Eli Lilly	III	12 July 2017	28 June 2027
12/07/2017	NCT03164616	Lung cancer	Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).	Stage IV NSCLC No prior chemotherapy or any other systemic therapy for metastatic NSCLC.	Durban, South Africa, 4091 Johannesburg, South Africa, 0001 Johannesburg, South Africa, 2193 Kraaifontein, South Africa, 7570 Pretoria, South Africa, 0001 Rondebosch, South Africa, 7700 Vereeniging, South Africa, 1930	Contact: AstraZeneca Cancer Study Locator Service 00 1-877-400-4656 email: AstraZeneca@emergingmed.com	AstraZeneca	Phase 3	01 June 2017	31 July 2019
	NCT03178851	Malignant Melanoma	Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma	Histologically confirmed Stage IV or unresectable Stage IIIc (locally advanced) melanoma	Cape Town Oncology Trials Cape Town GVI Constantiaberg Cape Town Johese Clinical Research Centurion Wits Clinical Research; Charlotte Maxeke Johannesburg Academic Hospital Cancercare Port Elizabeth Steve Biko Academic Hospital; Oncology Pretoria	global-roche-genentech-trials@gene.com Study ID Number: CO39721	Roche	Open label	19 June 2019	01 November 2019

Added	Go to www.clinicaltrials.gov and search this NCT Number for more detail	Indication	Title	abbreviated in and exclusion criteria - Go to www.clinicaltrials.gov and search NCT Number for more detail	Locations	Contact (please note some contacts are international) Use NCT number as reference	Sponsor	Phase	Start Date	Planned Completion Date
	NCT03296163	Non Small Cell Lung Cancer	A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC)	newly diagnosed or recurrent Stage IIIB/IV (defined by seventh edition of the TNM classification for Lung Cancer, 2010) non-squamous NSCLC not amenable to curative intent surgery, and not have received any systemic therapy for advanced disease	CancerCare George, South Africa Principal Investigator: Lee A Jones, MD CancerCare's Langenhoven Drive Oncology Centre Port Elizabeth, South Africa Principal Investigator: Louis Dupper, MD University of Pretoria - Steve Biko Academic Hospital - Dept of Medical Oncology Pretoria, South Africa Principal Investigator: Lydia Dreosti, MD	Contact: Susana Millán, PhD +34917711500 Susana.Millan@mabxience.com Contact: Amalia Flórez +34917711500 Amalia.Florez@mabxience.com	mAbxience S.A	Phase 3	06 February 2018	01 November 2019
	NCT03371017	Breast cancer	A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer (IMpassion132)	Histologically confirmed triple negative breast cancer(TNBC) that is either locally recurrent, inoperable and cannot be treated with curative intent or is metastatic	Wits Clinical Research; Charlotte Maxeke Johannesburg Academic Hospital Medical Oncology Centre of Rosebank; Oncology University of Pretoria Oncology Department; Medical Oncology Private Oncology Centre Pretoria	Reference Study ID Number: MO39193 global-roche-genentech-trials@gene.com	Roche	Phase 4	31 January 2018	31 July 2019